Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Recruiting, any sponsor type, condition "candidiasis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed180
11 trials
Showing 1 to 11, recently updated first.
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Pivotal-lookingRecruiting
Basilea PharmaceuticaIndustry
NCT05421858 · 450 participants (planned) · Start Dec 11, 2024 · Primary completion Jan 30, 2028
Drug: Fosmanogepix; Fosmanogepix and 6 more · For: Candidemia; Candidiasis, Invasive
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 146 sites in all
Queen's Medical CenterAcademic, hospital or other
NCT05753813 · 22 participants (planned) · Start Dec 15, 2023 · Primary completion Jan 30, 2027
Drug: Phexxi · For: Bacterial Vaginosis; Vulvovaginal Candidiasis
Sites: Honolulu, Hawaii
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05398809 · 70 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 1, 2027
Drug: Ruxolitinib · For: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced); Alopecia Areata
Sites: Bethesda, Maryland
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07202598 · 30 participants (planned) · Start Nov 12, 2025 · Primary completion Mar 31, 2031
Drug: Emapalumab · For: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis
Sites: Bethesda, Maryland
Sano Chemicals IncIndustry
NCT07521137 · 36 participants (planned) · Start Jun 4, 2026 · Primary completion Dec 31, 2026
Drug: OCF001 Intravaginal Gel; Placebo Gel · For: Candidiasis, Vulvovaginal
Sites: Birmingham, Alabama
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility StudyPivotal-lookingRecruiting
Guy's and St Thomas' NHS Foundation TrustAcademic, hospital or other
NCT05434104 · 114 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2027
Drug: Usual care · For: Bacterial Vaginosis; Candida Vaginal
Sites: London, United Kingdom · 2 sites in all
- PTX3-targeted Antifungal ProphylaxisPivotal-lookingRecruiting
Bochud Pierre-YvesAcademic, hospital or other
NCT03828773 · 410 participants (planned) · Start Feb 11, 2019 · Primary completion Nov 30, 2027
Drug: Posaconazole; Fluconazole · For: Candidiasis; Fungal Infection; Acute Myeloid Leukemia and 2 more
Sites: Ghent, Belgium; Bruges, Belgium; Leuven, Belgium · 9 sites in all
Melbourne HealthAcademic, hospital or other
NCT03717623 · 100 participants (planned) · Start Aug 1, 2019 · Primary completion Dec 30, 2025
Drug: Posaconazole pharmacokinetics · For: Posaconazole; Pharmacokinetics; Invasive Candidiases and 4 more
Sites: Parkville, Australia
- Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/VulvovaginitisPivotal-lookingRecruiting
AVVA Pharmaceuticals Ltd.Industry
NCT06835361 · 264 participants (planned) · Start Feb 29, 2024 · Primary completion Sep 30, 2025
Drug: Clotrimazole+Lactulose.; Canesten (Clotrimazole) and 1 more · For: Candidal Vulvovaginitis (ICD-10 Code: B37.3); Vulvovaginal Candidiasis (VVC)
Sites: Minsk, Belarus; Ryazan, Russia · 7 sites in all
- A Study of the Efficacy and Safety of WXSH0102 in Treating VCC PatientsPivotal-lookingRecruiting
Cisen Pharmaceutical CO., LTD.Industry
NCT06771063 · 108 participants (planned) · Start Jan 13, 2025 · Primary completion Jul 10, 2025
Drug: WXSH0102/placebo; fluconazole capsules/placebo · For: Vaginitis
Sites: Beijing, China · 2 sites in all
- The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis SymptomsPivotal-lookingRecruiting
Maastricht University Medical CenterAcademic, hospital or other
NCT05367089 · 252 participants (planned) · Start Aug 22, 2022 · Primary completion Apr 22, 2026
Drug: Fluconazole · For: Candidiasis, Vulvovaginal; Recurrent Candidiasis of Vagina
Sites: Heerlen, Netherlands; Maastricht, Netherlands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.